Compugen Immune Checkpoint Results Being Presented at Three Scientific Conferences
October 06 2014 - 7:08AM
Business Wire
Presentations at Annual International Cancer
Immunotherapy Symposium, Annual Meeting of the Society for
Immunotherapy of Cancer and the American College of
Rheumatology
Compugen Ltd. (NASDAQ: CGEN) today announced that certain
aspects of its predictive approach to therapeutics discovery as
applied to novel immune checkpoints will be presented in poster
sessions at three leading scientific conferences this month and
next. The presentations also include experimental results from some
of the immune checkpoint based product candidate programs
addressing cancer immunotherapy and autoimmune diseases now being
pursued by the Company:
- At the Cancer Research Institute’s 22nd
Annual International Cancer Immunotherapy Symposium, being held on
October 6-8, 2014 in New York City, Ilan Vaknin, PhD, Senior
Scientist, Immunology Research and Discovery at Compugen, will
present the predictive discovery of novel immune checkpoint targets
for cancer immunotherapy. Certain validation data relating to
CGEN-15049 and CGEN-15052, two of the eleven novel B7/CD28-like
immune checkpoint candidates discovered by Compugen, will be
included in the poster presentation.
- At the Society for Immunotherapy of
Cancer Annual Meeting, to be held November 6-9, 2014, in National
Harbor, MD, Galit Rotman, PhD, Chief Scientist, Therapeutics at
Compugen, will also present the predictive discovery of novel
immune checkpoint targets for cancer immunotherapy. Dr. Rotman’s
presentation will include certain validation data relating to
selected B7/CD28-like immune checkpoint candidates discovered by
the Company.
- At the American College of Rheumatology
Annual Meeting 2014, to be held on November 14-19, 2014, in Boston,
Iris Hecht, PhD, Principal Scientist at Compugen, will present
results for CGEN-15001 for the potential treatment of autoimmune
diseases such as rheumatoid arthritis, multiple sclerosis and type
1 diabetes. CGEN-15001 is a novel Fc fusion protein drug candidate
based on one of the eleven Compugen-discovered B7/CD28-like immune
checkpoint candidates.
About Compugen
Compugen is a leading drug discovery company focused on
therapeutic proteins and monoclonal antibodies to address important
unmet needs in the fields of immunology and oncology. The
Company utilizes a broad and continuously growing integrated
infrastructure of proprietary scientific understandings and
predictive platforms, algorithms, machine learning systems and
other computational biology capabilities for the in
silico (by computer) prediction and selection of product
candidates, which are then advanced in its Pipeline Program. The
Company's business model includes collaborations covering the
further development and commercialization of product candidates at
various stages from its Pipeline Program and various forms of
research and discovery agreements, in both cases providing Compugen
with potential milestone payments and royalties on product sales or
other forms of revenue sharing. Compugen’s wholly-owned U.S.
subsidiary located in South San Francisco is developing monoclonal
antibody therapeutic candidates against its novel drug targets. For
additional information, please visit Compugen's corporate website
at www.cgen.com.
Forward Looking Statement
This press release contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements can be identified by the use of
terminology such as “will,” “may,” “expects,” “anticipates,”
“believes,” and “intends,” and describe opinions about future
events. These forward-looking statements involve known and unknown
risks and uncertainties that may cause the actual results,
performance or achievements of Compugen to be materially different
from any future results, performance or achievements expressed or
implied by such forward-looking statements. Some of these and other
factors are discussed in the "Risk Factors" section of Compugen’s
most recent Annual Report on Form 20-F as filed with the Securities
and Exchange Commission as well as other documents that may be
subsequently filed by Compugen from time to time with the
Securities and Exchange Commission. In addition, any
forward-looking statements represent Compugen’s views only as of
the date of this release and should not be relied upon as
representing its views as of any subsequent date. Compugen does not
assume any obligation to update any forward-looking statements
unless required by law.
Compugen Ltd.Tsipi HaitovskyGlobal Media
Liaison+972-52-598-9892tsipih@cgen.com
Compugen (NASDAQ:CGEN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Compugen (NASDAQ:CGEN)
Historical Stock Chart
From Jul 2023 to Jul 2024